Abdulrahman Abonofal

Statistics

Publications

Citations

292

H-Index

Active since

2020

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Abdulrahman Abonofal is an author at The University of Texas MD Anderson Cancer Center specializing in pembrolizumab therapy, oncology, and immunotherapy.

ORCID

Publications per year

2020–2023

Publications

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Aung Naing, Funda Meric‐Bernstam, Bettzy Stephen et al. · Journal for ImmunoTherapy of Cancer · 2020 · 131 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract

Michael Frumovitz, Shannon N. Westin, Gloria Salvo et al. · Gynecologic Oncology · 2020 · 70 citations · Full text

Medicine, Oncology, Pharmacology +13

Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial

Kanwal Raghav, Bettzy Stephen, Daniel D. Karp et al. · Journal for ImmunoTherapy of Cancer · 2022 · 42 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial

Jeffrey How, Amir A. Jazaeri, Shannon N. Westin et al. · Investigational New Drugs · 2021 · 25 citations · Full text

Medicine, Gynecology, Oncology +17

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma

Chijioke Nze, Pavlos Msaouel, Mohamed H. Derbala et al. · Cancers · 2023 · 24 citations · Full text

Medicine, Immunology, Oncology +17

1–5 of 5